uniQure N.V. Interest Expense Nonoperating
uniQure N.V. (QURE) reported Interest Expense Nonoperating of $14.03 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-05-05
- uniQure N.V. interest expense nonoperating for the quarter ending 2026-03-31 was $14.03M, a 7.13% decline year-over-year.
- uniQure N.V. interest expense nonoperating for the quarter ending 2025-12-31 was $14.57M, a 2.04% decline year-over-year.
- uniQure N.V. interest expense nonoperating for the quarter ending 2025-09-30 was $16.72M, a 0.66% increase year-over-year.
- uniQure N.V. interest expense nonoperating for the quarter ending 2025-06-30 was $15.59M, a 3.50% decline year-over-year.
- uniQure N.V. interest expense nonoperating for fiscal 2025 was $61.99M, a 2.74% decline from fiscal 2024.
- uniQure N.V. interest expense nonoperating for fiscal 2024 was $63.74M, a 53.38% increase from fiscal 2023.
- uniQure N.V. interest expense nonoperating for fiscal 2023 was $41.56M, a 255.07% increase from fiscal 2022.
- uniQure N.V. interest expense nonoperating for fiscal 2022 was $11.70M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-03-31 | $14.03M 10-Q · filed 2026-05-05 | $28.60M derived: sum of 2 quarters · filed 2026-05-05 | $45.33M derived: sum of 3 quarters · filed 2026-05-05 | $60.92M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $14.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $31.29M derived: sum of 2 quarters · filed 2026-03-02 | $46.88M derived: sum of 3 quarters · filed 2026-03-02 | $61.99M 10-K · filed 2026-03-02 |
| 2025-09-30 | $16.72M 10-Q · filed 2025-11-10 | $32.31M derived: sum of 2 quarters · filed 2025-11-10 | $47.42M 10-Q · filed 2025-11-10 | $62.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $15.59M 10-Q · filed 2025-07-29 | $30.70M 10-Q · filed 2025-07-29 | $45.58M derived: sum of 3 quarters · filed 2026-05-05 | $62.19M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $15.11M 10-Q · filed 2026-05-05 | $29.98M derived: sum of 2 quarters · filed 2026-05-05 | $46.60M derived: sum of 3 quarters · filed 2026-05-05 | $62.75M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $14.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $31.49M derived: sum of 2 quarters · filed 2026-03-02 | $47.64M derived: sum of 3 quarters · filed 2026-03-02 | $63.74M 10-K · filed 2026-03-02 |
| 2024-09-30 | $16.61M 10-Q · filed 2025-11-10 | $32.77M derived: sum of 2 quarters · filed 2025-11-10 | $48.87M 10-Q · filed 2025-11-10 | $64.58M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $16.16M 10-Q · filed 2025-07-29 | $32.25M 10-Q · filed 2025-07-29 | $47.97M derived: sum of 3 quarters · filed 2026-03-02 | $63.41M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $16.10M 10-Q · filed 2025-05-09 | $31.81M derived: sum of 2 quarters · filed 2026-03-02 | $47.25M derived: sum of 3 quarters · filed 2026-03-02 | $54.09M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $15.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $31.16M derived: sum of 2 quarters · filed 2026-03-02 | $37.99M derived: sum of 3 quarters · filed 2026-03-02 | $41.56M 10-K · filed 2026-03-02 |
| 2023-09-30 | $15.44M 10-Q · filed 2024-11-05 | $22.28M derived: sum of 2 quarters · filed 2024-11-05 | $25.85M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $6.84M 10-Q · filed 2024-08-01 | $10.40M 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | $11.70M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |